By Kristine Mackin, Ph.D., Decision Resources Group (DRG)
Respiratory diseases are an appealing target for future microbiome development, with the combined asthma and chronic obstructive pulmonary disease (COPD) market approaching $30 billion by 2020 in the U.S. alone, and with significant unmet needs remaining in both markets.
By Jamie Cartland and Philip Winkworth, PA Consulting
It will be increasingly important for biopharma companies to employ ingenious strategies to access data already existing in the healthcare environment, moving away from solely building and owning data sets.
By Charles Christy,Lonza Pharma & Biotech
A new business and operating model may address the build or buy dilemma, offering an innovative and agile way to manage demand uncertainty and reduce the risks associated with early investment decisions.
Pharma manufacturers use a range of marketing channels to promote their prescription drug product, including sales representatives ‘hand carrying’ samples to healthcare practitioners within their territories.
Surface plasmon resonance (SPR) assays are used across the life cycle of a biopharmaceutical, from target identification through CQA determination, development, and ongoing quality control. This article focuses on concentration assays associated with late-stage development and biotherapeutic drug chemical manufacturing and control.